Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
Noosa News16 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News21 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News14 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News24 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common